(1) The purpose of communication is not just to deliver a message, but to effect a change in the recipient.
(2) The value of communication is to be judged not on its purpose or content, but on its effect on the recipient.
(3) Good communication is difficult. (4) Communication must be matched to the knowledge, social background, interest, purposes and need of the recipient. (5) Communication is effected not only by words, but also by attitudes, expressions and gestures. (6) If communication is to change behaviour, the required change in the recipient must be seen by him to have more advantages than drawbacks. (7) To make sure that a communication has succeeded, information about its effects (feedback), both immediate and subsequent, is needed.
(8) Communications demand effort, thought, time and often money.
The communication problems of the UK Centre are both internal and external.
Internal and Interdepartmental Communications
The UK Centre is made up of staff of the Medicines Division of the DHSS acting on behalf of Ministers as the licensing authority, and members of the various statutory advisory bodies. The Medicines Division has some 230 staff, including 18 doctors, 51 pharmacists, 19 scientific officers, 4 lawyers, a dental officer and 120 administrators, ranging from clerical assistants to the Under Secretary, who is in overall charge. In an organization of this size and diversity it is inevitable that problems of communication arise. A balance has to be struck between, on the one hand, the circulation of papers, whether to a limited number of individuals or to all members of the staffmany of whom will not have the time or inclination to plough through the mass that could arrive in the 'in tray' daily; and on the other hand, the holding of internal meetings which consume a considerable amount of valuable time. At times the need for urgency in dealing with a particular issue may mean that there is no time to consult a colleague who has a fringe interest in the subject. To compound these difficulties the Division is housed in four buildings.
The quantities of documents that have to be handled pose yet another problem, for if enquiries are to be dealt with efficiently, rapid access to the files is required. The number of files in regular use is immense (there is a separate file for each licence application): 35 000 Product Licences of Right and 4000 Product Licences for 800 companies, 600 Manufacturer's Licences, over 700 Clinical Trial Certificates and 1800 Wholesale Dealer's Licences.
In addition, files are maintained for the various statutory committees and sub-committees as well as for the countless separate policy issues that arise.
The statutory advisory bodies are the Medicines Commission and four Section 4 committeesnamely the Committee on Safety of Medicines, the Committee on the Review of Medicines, the British Pharmacopoeia Commission and the Committee on Dental and Surgical Materials. These committees have a total of 29 sub-committees as well as various ad hoc working parties; for example, the Medicines Commission Working Party on the Presentation of Medicines in Relation to Child Safety. The membership of these bodies approaches 300. With such numbers of distinguished experts in particular fields there is a considerable problem in achieving some degree of consistency within the UK's overall philosophy on medicines' control. In order to avoid misunderstandings, staff spend a considerable amount of time on liaison between committees.
When the officials and experts agree on the need for action, further steps are required. These may be simple or may involve consultation and preparation of a submission in order to secure Ministerial approval. In Another element that has been added in recent years is membership of the EEC. Apart from adopted directives, two pharmaceutical directives came into effect in November 1976 with the aim of harmonizing the control of medicines in member states. This has meant that some activities have had to be modified, and this has generated a new two-way flow of information. Representation of the UK on the Pharmaceutical Committee and Committee on Proprietary Medicinal Products poses problems of communication, especially with interpretation of directives and translation of documents.
Regular communication with international organizations such as the World Health Organization, the Council of Europe and other drug regulatory authorities is maintained. Fig 2 shows the main groups with whom we are in contact. These include Parliament; industry, in the form of trade associations and over 800 individual companies which vary from small organizations producing one or two minor remedies to major multinationals; the professional groupsdoctors, dentists, pharmacists, nurses, ophthalmic opticians, herbalists and many others (here we may also have to deal with individuals). Contacts must also be maintained with the Royal Colleges and a wide variety of associations; the health authorities at all levels; specialized media such as scientific journals; the mass media; and last but certainly not least the general public. Communications with the public are often indirect, filtered through the professions or the media, but there is also direct contact through correspondence. Linked with the public interest we include Parliament, for Members of Parliament often take up individual cases or causes through correspondence with the UK Centre or in Parliamentary questions. Any of these consultations with the groups mentioned above can be very arduous, involving effort, thought, time and often money -number 8 of Fletcher's principles.
External Communications
The Centre's prime objectives in any communications are: (1) To project a message in such a way that it is understood and acted upon in the way intended.
(2) To avoid premature disclosure by the mass media.
(3) To avoid distortion and sensationalization of the message. (4) To make appropriate use of its own 'feedback' information.
(5) To get the outside world to understand where responsibility lies in any particular issue.
On a subject of general interest, such as child safety containers, the UK Centre may have to consult with several hundred companies, organizations and individuals before determining the final advice which is to be given to Ministers. This process often involves two or three rounds of consultation letters followed by lengthy correspondence and meetings with individuals and organizations who have specific queries or objections.
However, despite efforts to involve all interested parties, cases occur where aggrieved organizations or individuals claim that they have not been consulted. Every effort is made to identify those who should be consulted before regulations or any proposals are circulated but because of the wide range of interests that may fall within the scope of Medicines Act matters, some organizations may be left out inadvertently, because their interest in the particular subject, or even their existence, is not known to us. On one occasion, a copy of a consultation document went astray in the post and the organization concerned became convinced that there was some Machiavellian plot to exclude it from consultation. In fact, it is very much in our interests to ensure full consultation at the formative stage of policy: indeed in certain instances the need for consultation is written into the Medicines Act, and failure to do so may invalidate legislation.
Another problem of communication is the interest of the mass media. Although on the whole cooperation by the media has been good and has been of great assistance in dealing with particular problems, difficulties have arisen. The UK Centre is fortunate in having professional advice from the DHSS Press Office; however, not all problems can be anticipated or forestalled. The main difficulty is that to make 'a good story' the media may sensationalize certain aspects and inject an unnecessary sense of urgency into a situation. Their handling of the story on high-dose cestrogen contraceptives illustrates some of these points.
In the late 1960s there was some concern about the growing incidence of thromboembolism amongst women using oral contraceptives containing high levels of aestrogen. The Committee on Safety of Drugs (CSD) (predecessor of the present Committee on Safety of Medicines) had been alerted to this problem by its adverse reporting system and decided to issue an early warning to alert doctors to the possible hazard before it was in a position to publish detailed findings for scientific scrutiny. Letters were posted to the profession, but unfortunately there was a 'leak' of information to the press before these reached all doctors. Sensational newspaper stories told of a major new risk. In fact there was no new risk, and what the CSD was doing was advising on how to reduce an already known small risk. However, the result was that hundreds of women were panicked into discontinuing the use of the pill, while doctors, confronted by a rush of anxious patients, reacted with justifiable anger and the CSD's secretariat had to deal with a stream of telephone calls and letters of complaint. Angry reactions also came from the pharmaceutical companies manufacturing oral contraceptives, who not unnaturally feared that the stories in the press would seriously damage their market. This event demonstrates how the message became distorted and the ultimate effect was to generate unnecessary anxiety, frustration, anger andmost important of allthe risk of a number of unwanted pregnancies. This particular episode also illustrates the general failure to appreciate the purpose of the UK Centre's early-warning system on adverse reactions. The warning letter was issued prior to the publication of the full scientific data so that doctors would be aware of the hazard as early as possible. However, both the professions and industry demanded to see all the evidence, which at that stage was available only in preliminary form. Obviously the use of early alerts can lead to the criticism that such action has been precipitate, but the alternative may be even more unacceptable. In the case in point, many women would have continued to be at greater risk if they had remained on the high dose estrogen preparations.
Problems with the beta-adrenoceptor blocking agent practolol (Eraldin) illustrate the care that must be taken with warnings, as well as the importance of an early inflow of information to the UK Centre. This agent was first marketed in 1970 for the treatment of angina, arrhythmias and hypertension. However, the UK Centre was not aware of any serious problem until Felix & Ive (1974) drew attention to a number of patients who had developed a rash resembling psoriasis, and Wright (1974) noted the association with serious eye changes. The Committee on Safety of Medicines (CSM) received an increasing number of reports of these and other problems, now known as the oculomucocutaneous syndrome. Such reactions must have occurred previously, but doctors either had not connected them with the use of practolol or if they had, had not reported them to the UK Centre. Obviously the professions had to be warned of the hazard, but at the same time the CSM was anxious to avoid undue anxiety in patients who were already at risk because of their cardiac disease. It also hoped to prevent the worsening of angina or hypertension or the precipitation of a serious arrhythmia by abrupt cessation of therapy. Therefore, great care was taken in the drafting of letters to doctors, in press handouts and later in the wording of an 'Adverse Reaction Series' leaflet. Despite these precautions serious anxieties were created in some quarters, whilst elsewhere the warnings were virtually ignored.
The UK Centre sends out important warnings in the Adverse Reactions Series, commonly known as 'yellow perils' because of the yellow paper on which they are printed. These are reserved for the most serious situations, in order to maintain their impact when needed. They are sent to all doctors and pharmacists individually, and also to the press to ensure wide coverage in the medical and professional journals. Other situations, while not warranting inclusion in the Adverse Reaction Series, may require the issue of some sort of warning letter, and for these, letters from com-mittee chairmen or senior members of staff are used.
Where there is less urgency, papers are published and the relevant committee issues a statement. This has the advantage ofdrawing attention to evidence, which permits full discussion in the journals. An example of this was the paper by Inman & Mushin (1974) on the hazards of repeated exposure to halothane. When this paper was published the CSM issued a statement drawing attention to its important implications. Unexpected opposition came from a number of anesthetists, but it is interesting to note that some of the most vocal critics subsequently published papers confirming the validity of the scientific basis on which advice had been given.
The UK Centre is constantly exploring new methods of communication and in 1975 the CSM instituted an occasional series of leaflets called 'Current Problems' with the main object of giving early notice of potential problems -in other words early warnings. It may also contain informative items designed to avoid possible problems; for example, in the second issue explanatory notes are given on insulin to help avoid confusion caused by the introduction of a number of new 'purified' preparations. If there is anything of broad general interest in Current Problems it is also put out as a press release to ensure maximum publicity.
Another medium for disseminating information is through the Annual Report of the Medicines Commission and the various committees. Although the readership is more limited than for the other items mentioned, it is a useful way of putting out a range of information, containing as it does brief notes on all the year's major activities. Mention should also be made of the letters that go out from industry giving warnings and advice on particular products. Many of these letters are drafted in close cooperation with the UK Centre.
A further method ofcommunicating information to interested bodies is through MAILthe Medicines Act Information Letterwhich is distributed quarterly to all licence holders and organizations which are normally consulted. Its function is to provide more routine communications, giving the 'state of play' on any regulations in hand, summarizing new developments and giving brief notes about any consultation documents. The letter is a very useful mechanism because, as mentioned earlier, consultation letters sometimes do go astray, and this provides an opportunity for recipients to check that they have seen all the items that are currently out for consultation.
Finally, there is the series of 'Medicines Act Leaflets,' commonly known as MALs. These give detailed information (mainly for the benefit of industry) on various aspects of our work. One of them, MAL 99, explained the broad arrangements for the control ofmedicines in the UK, and this has been particularly popular. Other leaflets advise on how different types of licence applications should be set out and what accompanying data should be submitted, and give notes for guidance on labelling, data sheets and other requirements. Considerable staff effort is devoted to the preparation and updating of MALs, but we consider this to be well worthwhile in providing comprehensive guidance to industry.
Problems do not stop when a letter or leaflet is written. There is another major problem in ensuring that it gets to the recipient, and that when it is received it is actually read, understood and acted upon. Mailing lists cannot always be kept up to date, and some doctors seek to keep their names off general lists in order to avoid being bombarded with advertising literature. Even when a leaflet actually arrives on a doctor's desk it may go promptly into the waste paper bin along with all the advertising literature, or receive only a cursory glance. Recently we conducted a small survey to see how many doctors receivedor more importantly, remembered receiving -Current Problems; from a random sample of 500 practising doctors the figure was only 50 %.
Communications must be geared to the knowledge, background and interest, purposes and need of the recipients (number 4 of Fletcher's principles). The following account illustrates this point. Towards the end of last year the UK Centre became aware of a baby tonic which was being imported illegally into the UK and sold without a product licence in some pharmacies and a number of Asian stores. It was sold under the name of 'Bal Jivan Chamcho Baby Tonic' and consisted of a metallic spoon containing a solid brown substance. It was packed in a white box with red printing, with instructions in English, Gujerati and Hindi 'for the treatment of Varadhcapillary, bronchitis, greenish diarrhoea, rickets, cough, convulsions, etc'. Analysis of the substance showed that it contained on average 1040 ppm of lead (the permitted lead content of food being 2 ppm) and the plating of the spoon itself contained 85 % of lead. Obviously urgent action was needed, but we had special difficulties because this product was sold mainly in Asian stores to immigrant mothers who had been accustomed to using this product in their home countries. An immediate warning was issued in the form of a notice to the newspapers and to the broadcasting and television authorities, while an urgent letter went to doctors alerting them to look out for possible lead poisoning in children. However, specific warnings needed to go to the Asian groups most at risk, and particularly to the mothers who might not have a good command of the English language. Therefore, particular efforts were devoted to securing warnings in the immigrant press, and the broadcasting and television authorities also cooperated by covering the subject in their Asian language programmes. The unusual technique was also adopted of accompanying the notices to the press and television with a photograph of the offending 'tonic' -both packet and contentsas it was considered that a large number of users might be illiterate. This action was coupled with legal steps to ban the import and sale of this 'baby tonic' by an emergency order under the Medicines Act (1976), and careful investigation by Medicines Act inspectors to track down and remove from sale supplies of the product. However, without this prompt and full communication with the public, a potentially serious situation could have developed before the more formal measures began to 'bite'. Subsequently, several doctors wrote in to say that our letter had enabled them to identify the cause of a number of cases of lead poisoning in Asian children.
Apart from written communication, a great deal of time is spent on personal communication by staff. Every day dozens of calls from industry and the professions asking for information and advice are dealt with. In addition, the staff are regularly invited to lecture at national and international meetings on various aspects of work; symposia or teach-ins are arranged for industry on how licence applications should be made; and meetings are held with professional and other groups.
